CINCINNATI , March 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today its increased commitment to the global fight against COVID-19 by making available zero cost samples of the company’s proprietary technologies to developers and manufacturers of molecular assays

CINCINNATI , March 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of immunoassay, molecular, and blood chemistry diagnostic testing solutions, today announced that it has received FDA-clearance for Meridian’s new Curian™ and Curian™ HpSA ® assay.

CINCINNATI , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), following the extremely successful launch of the Lyo-Ready qPCR mixes, is proud to introduce today its Air-Dryable qPCR Mix. This specialized master mix offers a cost-effective and easier alternative to

CINCINNATI and MODIIN, Israel , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) and Exalenz Bioscience Ltd. (TASE: EXEN) announced today that the two companies have entered into a definitive agreement for Meridian to acquire Exalenz for ₪6.10 per share in cash with an

CINCINNATI , Feb. 07, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2019 . First Quarter Fiscal 2020 Highlights: Diagnostics segment delivered nearly $35 million in revenues; fourth consecutive quarter

CINCINNATI , Jan. 27, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced a novel coronavirus, identified by Chinese authorities on January 7 and currently named 2019-nCoV, is a new strain that had not been previously identified in humans.

CINCINNATI , Jan. 23, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced the launch of a High-Specificity Pfu HS Mix that not only provides high-fidelity amplification, but also offers market-leading amplification for companion diagnostic (CDx) and clinical testing.

CINCINNATI , Jan. 15, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report first quarter 2020 financial results Friday, February 7, 2020 . Jack Kenny , Chief Executive Officer, and Bryan Baldasare ,